Can AbCellera Biologics Inc. cover its short-term obligations?

Its current ratio is 14.05 — current assets exceed current liabilities.

Where does AbCellera Biologics Inc.'s balance sheet data come from?

Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

AbCellera Biologics Inc. ABCL Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$128.51M-17.8%	$156.33M+17.3%	$133.32M-65.5%	$386.54M-18.8%
Restricted cash	$25M0.0%	$25M0.0%	$25M0.0%	$25M0.0%
Accounts receivable, net	$39.41M+23.2%	$31.98M—	——	——
Inventories	$6.34M—	——	——	——
Prepaid expenses and other current assets	$111.11M+65.5%	$67.14M+20.3%	$55.81M-26.0%	$75.41M+255%
Income taxes receivable	$55.7M+110%	$26.53M-21.5%	$33.79M-47.9%	$64.82M—
Total current assets	$728.23M-3.1%	$751.37M-13.8%	$871.99M-15.0%	$1.03B+10.3%
Goodwill	$47.81M0.0%	$47.81M0.0%	$47.81M0.0%	$47.81M0.0%
Intangible assets, net	$38.38M-8.9%	$42.11M-65.0%	$120.43M-8.4%	$131.5M-11.4%
Other non-current assets	$51.95M-46.2%	$96.54M+2.4%	$94.24M+103%	$46.33M+51.2%
Equity method investments	$32.5M-60.5%	$82.3M+24.8%	$65.94M-9.1%	$72.52M+44.1%
Accumulated depreciation	$30.94M-36.9%	$49.02M+41.2%	$34.72M+87.9%	$18.48M—
Total noncurrent assets	$628.72M+3.2%	$609.18M-1.1%	$616.11M+19.5%	$515.42M+32.6%
Total assets	$1.36B-0.3%	$1.36B-8.6%	$1.49B-3.4%	$1.54B+16.9%
Accounts payable	$25.23M-26.6%	$34.35M+20.1%	$28.6M+92.9%	$14.83M—
Accrued expenses	$10.76M+28.4%	$8.38M+8.7%	$7.71M+19.4%	$6.45M—
Deferred revenue	$13.53M0.0%	$13.52M-28.7%	$18.96M-12.3%	$21.61M+187%
Operating lease liabilities, current	$5.82M+25.8%	$4.62M-25.0%	$6.16M+10.3%	$5.58M+52.9%
Contract liabilities	$17.03M-11.4%	$19.22M+135%	$8.2M-58.0%	$19.52M-28.8%
Total current liabilities	$64.31M-16.1%	$76.61M-35.6%	$119.01M+0.6%	$118.32M-2.0%
Operating lease liabilities, non-current	$137.4M+126%	$60.74M-14.7%	$71.22M-7.1%	$76.68M+111%
Operating Lease Liabilities (Total)	$143.22M+119%	$65.36M-15.5%	$77.38M-5.9%	$82.26M+105%
Other non-current liabilities	$13.88M+93.7%	$7.17M+21.4%	$5.91M+91.4%	$3.09M+78.1%
Total noncurrent liabilities	$325.74M+43.0%	$227.86M+5.1%	$216.76M+14.5%	$189.31M+10.0%
Total liabilities	$390.05M+28.1%	$304.47M-9.3%	$335.78M+9.1%	$307.63M+5.1%
Common stock	$802.34M+3.2%	$777.17M+3.2%	$753.2M+2.6%	$734.37M+1.7%
Additional paid-in capital	$198.28M+19.2%	$166.36M+37.4%	$121.05M+63.3%	$74.12M+110%
Retained earnings	-$29.48M-125%	$116.93M-58.2%	$279.79M-34.4%	$426.19M+59.2%
Accumulated other comprehensive income (loss)	-$4.23M+3.3%	-$4.38M-155%	-$1.72M-23.7%	-$1.39M-597%
Total stockholders' equity	$966.9M-8.4%	$1.06B-8.4%	$1.15B-6.6%	$1.23B+20.2%
Total liabilities and stockholders' equity	$1.36B-0.3%	$1.36B-8.6%	$1.49B-3.4%	$1.54B+16.9%
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$155.25M-15.4%	$183.62M+14.3%	$160.61M-61.3%	$414.65M-17.3%
Cash, Cash Equivalents, and Marketable Securities	$405.31M-13.6%	$469.29M-25.2%	$627.27M+25.5%	$499.95M+103%
Accounts and accrued receivable	$58.29M+73.4%	$33.62M+9.9%	$30.59M-20.7%	$38.59M-76.0%
Cash Cash Equivalents And Short Term Investments	$533.83M-14.7%	$625.61M-17.7%	$760.59M—	——
Other current assets	$111.11M+65.5%	$67.14M+20.3%	$55.81M-26.0%	$75.41M+255%
Trading Securities in Marketable Securities	$32.5M+0.6%	$32.3M0.0%	$32.3M+74.6%	$18.5M—
Deferred Tax Assets and Other Non-Current Assets	$51.95M-46.2%	$96.54M+2.4%	$94.24M+103%	$46.33M+51.2%
Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments	$32.5M+0.6%	$32.3M0.0%	$32.3M+74.6%	$18.5M—
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Finite Lived Intangible Assets - Gross	$69.32M-23.9%	$91.13M-41.3%	$155.14M—	——
Government Assistance Asset, Non-Current	$33.59M-33.7%	$50.69M+40.6%	$36.05M—	——
Investments - Amortized Cost Basis	$32.5M+0.6%	$32.3M0.0%	$32.3M+74.6%	$18.5M—
Net Investment in Lease	$136.12M+104%	$66.65M-8.9%	$73.14M—	——
Intangible assets — net	——	——	——	——
Other intangible assets—net	$38.38M-8.9%	$42.11M-65.0%	$120.43M-8.4%	$131.5M-11.4%
Investments	$62.58M-24.0%	$82.3M+24.8%	$65.94M-9.1%	$72.52M+44.1%
Operating lease right-of-use assets	$136.12M+104%	$66.65M-8.9%	$73.14M—	——
Other non-current assets	$51.95M-46.2%	$96.54M+2.4%	$94.24M+103%	$46.33M+51.2%
Property and equipment, net	$428M+25.7%	$340.43M+18.3%	$287.7M+32.4%	$217.26M—
Operating Lease Right-of-Use Assets in Other Assets	$136.12M+104%	$66.65M-8.9%	$73.14M—	——
Software and Technology Licenses, Net	$51.95M-46.2%	$96.54M+2.4%	$94.24M+103%	$46.33M+51.2%
Accrued liabilities and other current	$50.78M-7.7%	$55M+10.9%	$49.58M-5.6%	$52.5M—
Accrued Manufacturing Costs	$10.76M+28.4%	$8.38M+8.7%	$7.71M+19.4%	$6.45M—
Accounts payable and other current liabilities (Note 11)	$25.23M-26.6%	$34.35M+20.1%	$28.6M+92.9%	$14.83M—
Compensation and benefits	$10.76M+28.4%	$8.38M+8.7%	$7.71M+19.4%	$6.45M—
Non-current Unearned Government Incentives	$174.45M+16.4%	$149.89M+56.3%	$95.92M—	——
Total debt	$143.22M+119%	$65.36M-15.5%	$77.38M-5.9%	$82.26M+105%
Common Stock Shares Issued	300.6M+1.6%	295.8M+0.2%	295.2M+1.9%	289.8M—
Additional paid-in capital	$198.28M+19.2%	$166.36M+37.4%	$121.05M+63.3%	$74.12M+110%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$802.34M+3.2%	$777.17M+3.2%	$753.2M+2.6%	$734.37M+1.7%
Available for sale investments	$405.31M-13.6%	$469.29M-25.2%	$627.27M+25.5%	$499.95M+103%
Cash and cash equivalents, end of period	$155.25M-15.4%	$183.62M+14.3%	$160.61M-61.3%	$414.65M-17.3%
Common stock, no par value (in dollars per share)	$0.00—	$0.00—	$0.00—	$0.00—
Common stock, shares issued (in shares)	$300.6M+1.6%	$295.76M+0.2%	$295.16M+1.9%	$289.78M—
Common Stock, Shares, Outstanding	$300.6M+1.6%	$295.76M+0.2%	$295.16M+1.9%	$289.78M—
Contract with Customer, Liability	$17.03M-11.4%	$19.22M-29.2%	$27.15M-34.0%	$41.13M+17.7%
Current portion of deferred government contribution	$8.98M+17.3%	$7.66M+7.7%	$7.11M+13.2%	$6.29M—
Trading securities, cost	$32.5M+0.6%	$32.3M0.0%	$32.3M+74.6%	$18.5M—
Finite-Lived Intangible Assets, Accumulated Amortization	$30.94M-36.9%	$49.02M+41.2%	$34.72M—	——
2028	——	——	——	——
2030	——	——	——	——
2031	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Gross Carrying Amount	$69.32M-23.9%	$91.13M-41.3%	$155.14M—	——
Government assistance, asset, current	——	——	——	——
Government assistance, asset, noncurrent	——	——	——	——
NOW Scheme contingency payable	$183.44M+16.4%	$157.55M+52.9%	$103.03M—	——
Government grants	——	——	——	——
Tax receivable within other current assets	$55.7M+110%	$26.53M-21.5%	$33.79M-47.9%	$64.82M—
Litigation settlement receivable	$36M—	——	——	——
Prepaid expenses and other	$9.67M+12.1%	$8.63M-60.8%	$22.02M+143%	$9.06M—
Property, Plant and Equipment and Operating Lease Right of Use Assets, Accumulated Depreciation and Amortization	$57.61M+45.1%	$39.72M+29.8%	$30.61M—	——
Property, Plant and Equipment and Operating Lease Right of Use Assets, before Accumulated Depreciation and Amortization	$485.62M+27.7%	$380.15M+19.4%	$318.3M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can AbCellera Biologics Inc. cover its short-term obligations?: Its current ratio is 14.05 — current assets exceed current liabilities.
Where does AbCellera Biologics Inc.'s balance sheet data come from?: Every line is extracted from AbCellera Biologics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.